{"id":"travoprost-timolol-azopt-brimonidine","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Eye pain"},{"rate":"5-10%","effect":"Blepharitis"},{"rate":"5-10%","effect":"Dry mouth"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Travoprost, Timolol, Azopt, and Brimonidine work together to reduce intraocular pressure in patients with glaucoma or ocular hypertension. By increasing uveoscleral outflow and decreasing aqueous humor production, these medications help to alleviate symptoms and slow disease progression. The combination of these mechanisms provides a comprehensive approach to managing glaucoma and ocular hypertension.","oneSentence":"Travoprost is a prostaglandin F2α analogue that lowers intraocular pressure by increasing uveoscleral outflow, while Timolol is a non-selective beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production. Azopt is a carbonic anhydrase inhibitor that decreases intraocular pressure by reducing aqueous humor production. Brimonidine is an α2-adrenergic receptor agonist that decreases intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:56.251Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma, Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT07074782","phase":"","title":"Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues","status":"NOT_YET_RECRUITING","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2026-01","conditions":"Glaucoma","enrollment":1500},{"nctId":"NCT00981786","phase":"PHASE4","title":"24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2009-08","conditions":"Glaucoma","enrollment":51},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT02730871","phase":"PHASE4","title":"Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2016-06-24","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":173},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT01004900","phase":"PHASE3","title":"Intraocular Pressure (IOP) Lowering Effect of Selective Laser Trabeculoplasty Versus Prostaglandin Analogues in Angle Closure Glaucoma","status":"UNKNOWN","sponsor":"Singapore Eye Research Institute","startDate":"2009-06","conditions":"Glaucoma","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Travoprost/ Timolol/ Azopt/ Brimonidine","genericName":"Travoprost/ Timolol/ Azopt/ Brimonidine","companyName":"Singapore Eye Research Institute","companyId":"singapore-eye-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Travoprost is a prostaglandin F2α analogue that lowers intraocular pressure by increasing uveoscleral outflow, while Timolol is a non-selective beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production. Azopt is a carbonic anhydrase inhibitor that decreases intraocular pressure by reducing aqueous humor production. Brimonidine is an α2-adrenergic receptor agonist that decreases intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow. Used for Glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}